Last reviewed · How we verify
Marketed Pramipexole ER
Marketed Pramipexole ER is a Dopamine D2/D3 receptor agonist Small molecule drug developed by Pharma Two B Ltd.. It is currently in Phase 3 development for Parkinson's disease (motor symptoms), Restless legs syndrome. Also known as: PramiER.
Pramipexole is a dopamine D2/D3 receptor agonist that stimulates dopamine signaling in the brain to improve motor control and reduce symptoms of Parkinson's disease.
Pramipexole is a dopamine D2/D3 receptor agonist that stimulates dopamine signaling in the brain to improve motor control and reduce symptoms of Parkinson's disease. Used for Parkinson's disease (motor symptoms), Restless legs syndrome.
At a glance
| Generic name | Marketed Pramipexole ER |
|---|---|
| Also known as | PramiER |
| Sponsor | Pharma Two B Ltd. |
| Drug class | Dopamine D2/D3 receptor agonist |
| Target | Dopamine D2 receptor, Dopamine D3 receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Pramipexole binds to and activates dopamine D2 and D3 receptors, particularly in the striatum and other basal ganglia structures. By mimicking dopamine's action, it compensates for the loss of dopamine-producing neurons characteristic of Parkinson's disease, thereby improving motor symptoms such as tremor, rigidity, and bradykinesia. The extended-release formulation allows for once-daily dosing with more stable plasma levels compared to immediate-release formulations.
Approved indications
- Parkinson's disease (motor symptoms)
- Restless legs syndrome
Common side effects
- Nausea
- Dizziness
- Somnolence
- Hallucinations
- Orthostatic hypotension
- Headache
- Constipation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Marketed Pramipexole ER CI brief — competitive landscape report
- Marketed Pramipexole ER updates RSS · CI watch RSS
- Pharma Two B Ltd. portfolio CI
Frequently asked questions about Marketed Pramipexole ER
What is Marketed Pramipexole ER?
How does Marketed Pramipexole ER work?
What is Marketed Pramipexole ER used for?
Who makes Marketed Pramipexole ER?
Is Marketed Pramipexole ER also known as anything else?
What drug class is Marketed Pramipexole ER in?
What development phase is Marketed Pramipexole ER in?
What are the side effects of Marketed Pramipexole ER?
What does Marketed Pramipexole ER target?
Related
- Drug class: All Dopamine D2/D3 receptor agonist drugs
- Target: All drugs targeting Dopamine D2 receptor, Dopamine D3 receptor
- Manufacturer: Pharma Two B Ltd. — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Parkinson's disease (motor symptoms)
- Indication: Drugs for Restless legs syndrome
- Also known as: PramiER
- Compare: Marketed Pramipexole ER vs similar drugs
- Pricing: Marketed Pramipexole ER cost, discount & access